Objective To evaluate the impact of substance abuse on pediatric hepatitis C virus (HCV) prevalence, we examined geographic and demographic data on inpatient hospitalizations in children with HCV.
H epatitis C virus (HCV) is well-known worldwide as a cause of chronic liver disease in adults and contributes to significant healthcare use.
1,2 After a sustained decline in new HCV cases, in recent years there has been a significant increase in HCV incidence in adults in many areas, primarily associated with the use and abuse of intravenous heroin and prescription opioids. [3] [4] [5] What is less well-known is the current burden of HCV in children and how the substance abuse related HCV cases among adults has affected the pediatric population.
There are approximately 50 000 children living with chronic HCV in the US and 11 million children under 15 years old worldwide. 6, 7 As direct-acting antivirals (DAAs) are approved for adolescents and continue to be studied in younger children, defining the burden among children now will be essential to break the cycle of HCV transmission. 8, 9 As the costs and benefits of DAA use in children are considered, the lack of information about the current burden of HCV becomes more apparent. To help address this knowledge gap, we sought to first define the burden of inpatient HCV among pediatric populations, risk factors for infection, as well as the socioeconomic and geographical characteristics of disease.
Methods
We examined hospitalizations in children using the Kids' Inpatient Database (KID), a part of the Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality, in accordance with their data use agreement. The KID is the largest publicly available pediatric inpatient database in the United States; all payors are included. The KID contains de-identified patientand hospital-level discharge data across 44 states and more than 4100 community hospitals in 3-year increments. Data from 2006, 2009, and 2012 were included in this analysis. Approximately 3 million discharges are collected annually accounting for a weighted estimation of 7 million pediatric hospitalizations. KID is designed to facilitate national and regional studies of both rare and common pediatric diseases.
10 Of note, state-level federal information process standards identifiers were included in the 2006 and 2009 datasets, but were removed from the 2012 version.
We chose to compare HCV hospitalization with hospitalizations for appendectomy as a control group, hypothesizing that appendicitis represents a common pediatric medical problem that is not bound by geographic or demographic We hypothesized that differential age distributions existed between patients with HCV and patients with appendectomies. As a result, we performed frequency matching of HCV and randomly sampled appendectomy cases using a 1:3 ratio within each a priori defined age category: ≤1, 2-3, 4-6, 7-9, 10-12, 13-15, 16-18, and ≥19 years of age.
Statistical Analyses
The patient discharge weight with a primary sampling unit specification and strata indicator were used to account for the complex survey design of KID. We report unadjusted and adjusted statistics comparing demographic characteristics and substance abuse between HCV and appendectomy patients.
Taylor series linearization variance estimation was used for standard error calculations. Statistical significance was determined from a Wald test, which was based on an adjusted F statistic. Multivariable logistic models were used to predict the odds of HCV and the odds of substance abuse. All analyses were conducted using SAS (v9.4, SAS Institute Inc, Cary, North Carolina). We used the 2009 KID dataset to obtain state-specific rates for HCV and substance abuse, per 10 000 hospitalizations. This dataset was selected because it is the most recent dataset with state and federal information process standards identifiers. We ran a Pearson product-moment correlation to determine the relationship between state-level HCV and substance abuse. Last, we provide choropleth maps to demonstrate regional variability across the US.
Results
Patient demographics for all children hospitalized with HCV and appendicitis are shown in Table I . In the pooled analysis THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 192 • January 2018 of the 3 time samples, the proportion of females admitted with HCV was greater than with appendicitis (67% vs 42%; P < .001). Compared with appendicitis admissions, a greater proportion of children with HCV were white (61% vs 48%; P < .001), from the South (39% vs 33%; P < .001), and in the lowest zip code median income quartile (37% vs 27%; P < .001).
Substance abuse was more prevalent as well among children with HCV (33% vs 0.2%; P < .001).
From 2006 to 2012 nationally, we observed a 37% increase in the rate of hospitalizations of children infected with HCV (from 2.69 to 3.69 per 10-000 admissions; P < .001). The mean age of children hospitalized with HCV was 17.6 years (95% CI, 17.4-17.8). HCV cases among those 18-20 years of age represented 65% of the total HCV diagnoses, with an increase over the years sampled from 1.65 to 2.51 cases per 10 000 admissions (P < .001 for trend). One-third of HCV cases were coded as having a substance use disorder; it was the primary diagnosis for 3.96% of the total HCV sample, with the prevalence of substance use overall among children with HCV increasing from 24.6% in 2006 to 40.8% in 2012 (P < .001).
Because state identifiers were removed from the 2012 dataset, we performed a geographic analysis of HCV prevalence using the 2009 data. West Virginia had the highest prevalence in the US (9.48 per 10 000 admissions). States in the Northeast (Massachusetts, Maine, New Hampshire, and Vermont) and the Appalachian region (West Virginia, Kentucky, Tennessee, and Pennsylvania) were all represented amongst states in the top 2 quartiles of inpatient pediatric HCV prevalence (Figure, A) . We also performed a geographic analysis of substance abuse hospitalizations, and all of the states mentioned were also represented in the top 2 quartiles on this choropleth map (Figure, B) . When the prevalence data for HCV were plotted against the substance abuse prevalence, the Pearson correlation coefficient was 0.6.
Predictors of HCV Infection
We conducted a logistic regression analysis to examine predictors of HCV infection (Table II) 
Predictors of Substance Abuse
We performed a logistic regression to examine further the association between HCV and substance abuse (Table III) . Using 2006 as a referent time point, the odds for substance abuse increased over the analyzed time period (2012 cycle OR, 2.08; 95% CI, 1.67-2.61; P < .0001). Compared with age-matched patients who underwent appendectomy, pediatric patients diagnosed with HCV had a greater odds of substance abuse (OR, 273.82; 95% CI, 183.57-408.43; P < .0001). Patients younger than 18 years, males, and Caucasians all had greater odds for substance abuse. The Northeast region had the greatest odds for substance abuse (OR, 1.95; 95% CI, 1.45-2.62; P < .0001). 
Discussion
We found that, from 2006 to 2012, the number of hospitalizations nationally of children infected with HCV increased by 37%. The majority of these patients were adolescents, of whom one-third also had a substance use disorder. Overall, the prevalence of substance use among children with HCV increased from 27% in 2006 to 42% in 2012 (P < .001). As illustrated by the maps we generated using our case data, certain regions were affected disproportionately. The Northeast region had the highest HCV prevalence, followed by several Appalachian states, including West Virginia, Kentucky, Tennessee, and Pennsylvania. These results highlight alarming trends in HCV-infected children that mirror what has been described in adults nationally and in the Appalachian states. They demonstrate that the current epidemic of new HCV cases has not spared children, and in particular, adolescents. These results also likely represent a significant underestimate of the true burden, because children would likely not manifest symptoms from HCV and would not require hospitalization. 11 The increase in the number of hospitalized children with HCV likely represents a true increase in disease prevalence rather than just an increase in overall hospitalizations. Other common reasons for hospitalizations among children, such as appendicitis, stayed constant over the same time period, suggesting that KID inpatient sampling remained relatively stable. The natural history of HCV in children strongly suggests that these adolescents are too young to present with complications of chronic liver disease. [12] [13] [14] The increase in HCV prevalence is associated with an increase in the number of diagnoses for substance abuse. Because children with HCV do not frequently need hospitalization, the increase in hospitalizations was likely driven in large part by the need for substance abuse treatment. Over a similar time period (2005-2011), Canadian researchers found that, among Canadian street youth, misuse of prescription opioids was increasing, but it was street drugs (heroin, cocaine, crystal methamphetamine) that increased the hazard of HCV seropositivity. 15 In our analysis, we found that girls had greater odds for both substance abuse and HCV infection. Although this may be a result of selection bias in that boys are less likely to present for medical care and women access inpatient care via pregnancy and child birth, it underscores a further concerning trend of HCV infection among women of childbearing age. Although perinatal transmission occurs uncommonly, most studies cite a transmission rate of approximately 5% that only occurs in women with HCV viremia 16, 17 ; it remains a source of continued viral transmission. The greater HCV prevalence among women may also be seen as an opportunity. Although not yet approved in pregnancy, some DAA have a US Food and Drug Administration pregnancy category of B, suggesting safe use in pregnancy. Because the current duration of therapy is shorter than gestation, HCV could be eradicated in the mother and the risk of perinatal transmission to the fetus reduced during this time.
Major developments in recent years have changed the scientific landscape for HCV and now present an opportunity for detailed studies of children with HCV. Highly efficacious DAAs have been approved for the treatment of adults with HCV, yielding a cure rate exceeding 90%-95%. [18] [19] [20] [21] [22] [23] These agents offer other benefits: relatively few side effects, all oral dosing, and a dramatically reduced duration of therapy (8-12 weeks). However, they are expensive, costing approximately $50 000-80 000 for a treatment course for 1 patient. 24 When the standard of care was pegylated interferon and ribavirin, and the sustained virologic response rate was only 50%, the case for treating children was more difficult to make. DAAs are now approved for use in adolescents with a published cure rate of 98%. 8, 9 As the costs and benefits of using DAAs in children are considered, the lack of good evidence on the current healthcare burden of HCV for these patients becomes more apparent.
Unless all facets of the population are treated, even DAAs with 100% cure rate will not curb the spread of HCV. [25] [26] [27] Even though resources are available for adults with substance abuse and/or mental health issues, 28 the extent to which these resources are available to pediatric populations is unknown. These results underscore the point that adolescents need to be considered and included in public health efforts to address HCV in the population, and these efforts should be well-integrated with substance abuse treatment programs.
Despite the limitations of examining inpatient admissions in children with HCV, we were able to find significant changes in cases over the study period. Still, this analysis likely far underestimates the number of infected individuals, and only a widespread population-based study screening adolescents would offer details that are more accurate. Regardless, these results strongly suggest that public health efforts to prevent and treat HCV will also need to include teenage patients.
There are several limitations that should be considered when reviewing these results. Any analysis of administrative data that relies on International Classification of Diseases, 9th edition, coding assumes that these codes accurately reflect the condition of interest. Although we attempted to be as comprehensive as we could, some patients may have been coded under other liver-related conditions. Given that our findings strongly mirror what has been described in adults, it unlikely that this had a large impact on our findings. Our analysis was limited to inpatient admissions and was not designed to capture children in other settings. We have acknowledged that this could underestimate the total burden of disease. We used appendicitis as a control condition that is well-known to have an incidence and prevalence that is consistent across different segments of the population. There might be unforeseen factors that might have also affected the rates of our control condition that would then influence our statistical analysis. Finally, our geographic analysis was limited beyond 2009, because the 2012 dataset contained no state-level federal information process standards identifiers. Again, the states identified in 2009 mirror prior reports from the Centers for Disease Control and Prevention, so it is likely that the 2012 data would be consistent.
Efforts to control HCV in this country will need to account for pediatric patients, both with intensive education and prevention strategies as well as integrated DAA treatment and drug rehabilitation. ■
